Piton Therapeutics

Piton (“Pee-ton”) is pioneering the development of life-changing, first-in-class therapeutics for chronic conditions with limited therapeutic options. The company employs a proprietary platform to discern the gut microbiome’s role in the cause and progression of disease. Therapeutics are developed to precisely target pathogenic pathways in the gut lumen. AI capabilities efficiently identify drug candidates with desired characteristics which are validated in the company’s lab. Products consist of small molecule drugs. Piton does NOT develop live bacterial therapeutics (LBTs) or seek to modify the composition of microbiota in the gut. Piton’s lead pipelines, IBD/Ulcerative Colitis & Autism Spectrum Disorder, target unmet needs in markets with 5 million and 50+ million patients, respectively. Parkinson’s Disease constitutes a third area of focus. Piton's therapeutic approach for Ulcerative Colitis uniquely targets a cause of the disease for a sub-type constituting ~45% of the patient population. The approach has strong support in the clinical community and represents a potential ‘paradigm change’ in the treatment of the disease. In-human trials are anticipated in 2025. Recently published research suggests that Piton’s therapeutic strategy for UC may have application in the treatment of type 2 diabetes and weight loss management. Piton’s therapeutic approach for Autism Spectrum Disorder has been validated in successive, in-vivo experiments. Several drug candidates are under consideration for what could be the first approved drug to treat the core symptoms of ASD. Application of Piton’s discovery platform for Parkinson’s Disease led to the discovery of a causative hypothesis and a target for novel therapeutic intervention. Given strong links between this hypothesis and many chronic diseases, including Intestinal Bowel Disease (IBD), this program may hold cross-disease blockbuster potential. Piton has strong IP Portfolio & a stellar team of active advisors.